Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
A phase 1/2 trial of Fludarabine and Cyclophosphamide in gastric & gastro-oesophageal junction cancer, run by Beijing Biotech, now recruiting.
Overview
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer is a phase 1/2 interventional study registered as NCT07551362 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DT-CAR-NK, Fludarabine and Cyclophosphamide.
Similar pages
not linked directly; found by shared links- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialClinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.